08:57 AM EDT, 10/15/2024 (MT Newswires) -- Knight Therapeutics ( KHTRF ) on Tuesday said its Mexican affiliate has obtained regulatory approval for Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that aren't eligible for autologous stem cell transplantation.

The treatment is expected to launch in the first half of next year.

DLBCL is the most common subtype of non-Hodgkin lymphoma and presents an aggressive clinical profile.

In September 2021, Knight signed a supply and distribution agreement with Incyte for the exclusive rights to distribute tafasitamab in Latin America.